Different Effects of Traditional Chinese Medicines Containing Similar Herbal Constituents on Prednisolone Pharmacokinetics

MASATO HOMMA, KITARO OKA, KEN IKESHIMA, NORIYUKI TAKAHASHI*, TOMOYUKI NIITSUMA†, TOSHIAKI FUKUDA† AND HISAO ITOH†

Department of Clinical Pharmacology, Tokyo College of Pharmacy, Horinouchi 1432-1, Hachioji, Tokyo 192-03, *Department of Pharmacy, Tokyo Medical College Hospital, Shinjuku-ku, Tokyo 160, and †Department of Third Internal Medicine, Tokyo Medical College Hospital, Shinjuku-ku, Tokyo 160, Japan

Abstract

Three major traditional Chinese medicines (TCM), Sho-saiko-To, Saiboku-To, and Sairei-To, consist of similar herbal prescriptions containing glycyrrhizin, which is a strong inhibitor of 11β -hydroxysteroid dehydrogenase. We performed cross-over open trials in healthy subjects to clarify prednisolone pharmacokinetics on co-administration of these preparations.

All subjects received a single oral dose of 10 mg prednisolone before oral treatment with one of the test preparations. After a 2-week wash-out interval, they received one of the test preparations for three days at daily doses of 7.5 or 9.0 g. On the third study day, 10 mg prednisolone was administered orally in combination with the test preparation. Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L⁻¹ (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L⁻¹ (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group. AUC ratios of prednisolone, which reflect the 11 β -hydroxysteroid dehydrogenase activity, increased in the Sho-saiko-To group (P < 0.01), decreased in the Saiboku-To group (P < 0.01), and did not change in the Sairei-To group after the treatments. Similar results were observed in ratios of endogenous cortisone to cortisol.

Because of the equal glycyrrhizin content in all three preparations, it was unexpected that the 11β -hydroxysteroid dehydrogenase effect was different amongst the three groups. These observations suggest that some unknown metabolic enzyme modifiers, promoters or inhibitors, may be involved in these traditional treatments.

Glucocorticoids comprise the most potent class of antiinflammatory and immunosuppressive agents for treatment of acute and chronic disease states. However, long-term use of glucocorticoids has been restricted owing to side-effects (Fauci et al 1976). To use minimal doses of glucocorticoid without loss of symptom control, non-steroidal agents with different mechanisms of action have been co-administered with reduced doses of glucocorticoid. An alternative approach has recently been reported using a glucocorticoid metabolic enzyme inhibitor. Mackenzie et al (1990) showed that glycyrrhetinic acid decreased blood concentration ratios of cortisone to cortisol in healthy volunteers. A therapeutic application can be found in the topical use of cortisol ester (Teelucksingh et al 1990). Glycyrrhetinic acid inhibits 11β -hydroxysteroid dehydrogenase which mediates dehydrogenation of the 11β -hydroxyl substituent (Monder et al 1989). Also, glycyrrhetinic acid is an active form of glycyrrhizin, which is a liquorice glycoside contained in Glycyrrhiza glabra.

Three major traditional Chinese medicines, Sho-saiko-To, Saiboku-To, and Sairei-To, contain *G. glabra* and have been occasionally prescribed for collagen diseases, severe asthma, and nephrotic syndrome in conjunction with prednisolone (Senaga & Kawashima 1986; Tani et al 1986; Nagano et al 1988). The herbal constituents of these preparations are listed in Table 1. However, it is not known whether steroid dose-sparing effects of such a complex matrix as mixed herbal medicines are attributable simply to enzyme inhibition. In the present paper, we investigated the effects of the three preparations on prednisolone pharmacokinetics, focusing our attention on the major metabolic pathway via 11β -hydroxy-dehydrogenation.

Materials and Methods

Preparations

The traditional Chinese medicine preparations used in this study were mixtures of dry aqueous extracts of constituent herbs as indicated in Table 1. Sho-saiko-To, Saiboku-To and Sairei-To were obtained from Tsumura Co. (Tokyo, Japan). They are fine granular formations for ethical use. The prescription guidelines described in the Japanese Pharmacopoeia recommended daily doses of 7.5, 7.5 and 9.0 g for Sho-saiko-To, Saiboku-To and Sairei-To, respectively.

Determination of glycyrrhizin

Amounts of glycyrrhizin contained in the preparations were

Correspondence: M. Homma, Department of Clinical Pharmacology, Tokyo College of Pharmacy, Horinouchi 1432-1, Hachioji, Tokyo 192-03, Japan.

MASATO HOMMA ET AL

Plant name	Family	Composition (%; w/w)			
		Sho-saiko-To	Saiboku-To	Sairei-To	
Bupleurum falcatum L.	Umbelliferae	29.2	20.6	17.5	
Pinellia ternata Breitenbach	Araceae	20.8	14.7	12.5	
Scutellaria baicalensis Georgi	Labiatae	12.5	8.8	7.5	
Zizyphus vulgaris Lam.	Rhamnaceae	12.5	8.8	7.5	
Panax ginseng C. A. Meyer	Araliaceae	12.5	8.8	7.5	
Glycyrrhiza glabra L.	Leguminosae	8.3	5.9	5.0	
Zingiber officinale Roscoe	Zingiberaceae	4.2	3.0	2.5	
Poria cocos Wolf.	Polyporaceae	-	14.7	7.5	
Magnolia officinalis	Magnoliaceae	-	8.8	-	
Perillae frutescens Britton var. acuta Kudo	Labiatae		5.9	-	
Alisma orientale Juzepczuk	Alismaceae	_		12.5	
Atractylodes lancea D. C.	Compositae		-	7.5	
Polyporus umbellatus Fries	Polyporaceae	_	-	7.5	
Cinnamomum cassia Blume	Lauraceae	-	-	5.0	

Table 1. Herbal compositions of Sho-saiko-To, Saiboku-To and Sairei-To.

determined by reversed-phase high-performance liquid chromatography (HPLC) (Ogawa et al 1976). Specimens of 100 mg granules were added to 10 mL 50% aqueous ethanol and stirred for 20 min at 65°C. After cooling to room temperature (21°C), the mixtures were centrifuged at 2000 g for 10 min. Ten microlitres of the supernatant was analysed by HPLC. Our HPLC apparatus was a U-880 series obtained from Jasco (Tokyo, Japan), equipped with a conventional ODS-column (Finepack STL, $125 \times 4 \text{ mm i.d.}$, Jasco). The solvent system was 0.05 M phosphate/methanol (5:2, v/v) with a flow rate of 1.0 mLmin^{-1} . Direct peak height calibration of glycyrrhizin was conducted at a wavelength of 254 nm and sensitivity of 0.04 aufs. The detection limit of glycyrrhizin was 20 ng injected and coefficients of variation were less than 3% (Ogawa et al 1976).

Subjects and study design

Two-period cross-over open trials were completed by healthy male volunteers. Mean age and body weight of the subjects were $21\cdot8 \pm 1\cdot2$ years and $63\cdot3 \pm 6\cdot8$ kg in the Sho-saiko-To group (n = 6), $23\cdot5 \oplus 1\cdot5$ years and $61\cdot3 \pm 4\cdot5$ kg in the Saiboku-To group (n = 9) and $22\cdot4 \pm 1\cdot9$ years and $62\cdot0 \pm 7\cdot1$ kg in the Sairei-To group (n = 7). All subjects were non-smokers and were not taking any medication known to influence glucocorticoid hepatic metabolism or pharmacokinetics.

The subjects in each group were further divided randomly into two groups and participated in both control and test studies in different test periods two weeks apart. The control studies were carried out by administering single 10 mg doses prednisolone orally at 1000 h. In the test studies, the subjects were given an assigned preparation three times a day, 2h after meals for three days. Daily doses of Sho-saiko-To and Saiboku-To were 7.5 g ($2.5 \text{ g} \times 3$) and that of Sairei-To, $9.0 \text{ g} (3.0 \text{ g} \times 3)$. On the third day, preparations were coadministered with 10 mg prednisolone at 1000 h. Blood samples for determination of prednisolone and prednisone were drawn before and 1, 2, 4, 6, and 8 h after prednisolone administration. Blood samples for cortisol and cortisone determination were taken at around 1000 h on the first and third day before the administration of the preparations. Serum specimens were separated by centrifugation at 1500 g for 10 min and stored at -20° C until analysis.

Our study protocol was approved by the ethics committee of our hospital and all subjects gave their informed consent.

Determination of serum glucocorticoids

Serum concentrations of prednisolone, prednisone, cortisol, and cortisone were determined simultaneously by HPLC in combination with rapid-flow fractionation (Oka et al 1984, 1987). Glucocorticoids including dexamethasone as an internal standard were fractionated into small amounts of dichloromethane solution. We used 0.5 mL serum and 50 ng internal standard. Our HPLC system was a U-880 series (Jasco, Tokyo, Japan) equipped with a conventional silicagel column LiChrosorb Si 60, 5 μ m, 250 × 4 mm i.d. (Cica-Merck, Tokyo, Japan). The solvent system was water/ methanol/dichloromethane/*n*-hexane (0.1:6.0:30.0:63.9)at a flow rate of 1.5 mL min⁻¹. Detection wave-length was set at 245 nm and sensitivities, 0.0025-0.005 aufs. The analytical detection limit for each glucocorticoid was 1 ng mL⁻¹ and the coefficient of variations were less than 5%. Other analytical accuracies were similar to those previously described (Oka et al 1984, 1987).

Calculations

Areas under the serum drug concentrations (AUC) were calculated for prednisolone and prednisone according to the linear trapezoidal rule, extrapolated to 10 h after administration. The elimination rate constant (k_e) was calculated by fitting individual data from the terminal portion of the serum prednisolone concentration-time profile with a log-linear regression equation using the least-squares method. The corresponding elimination half-life (t_2) was calculated by dividing ln 2 by k_e . Individual systemic availability of

Table 2. Glycyrrhizin content of Sho-saiko-To, Saiboku-To and Sairei-To.

Herbal remedy	Daily dose	Glycyrrhizin (mg) in		
	(g)	l g of preparation	Daily dose	
Sho-saiko-To	7.5	8.8	66.0	
Saiboku-To	7.5	8.5	63.5	
Sairei-To	9.0	6.7	60.3	




FIG. 1. Plot of serum concentrations of prednisolone (\bullet , \bigcirc) and prednisone (\blacktriangle , \triangle) or after administration of 10 mg prednisolone alone (control, ---) and with the test preparation (-). *P < 0.05, **P < 0.01 compared with control values.

prednisolone was not determined in this study; therefore, we used the dosage amount to calculate total body clearance on the assumption that the availability of prednisolone equals 1. Thus, total body prednisolone clearance (CL) was determined by dividing the dose (10 mg) by the AUC. The apparent distribution volume (Vd) was calculated by dividing CL by k_e .

The pharmacokinetic parameters of prednisolone were compared statistically between the control and the test studies, using Student's *t*-test for paired observations. Differences were considered to be significant for P < 0.05.

Results

Glycyrrhizin content

The three preparations contain G. glabra as a common constituent herb as shown in Table 1. This herb has been known to contain the strong 11β -hydroxysteroid dehydrogenase inhibitors, glycyrrhizin and glycyrrhetinic acid (Ogawa et al 1976; Ojima et al 1990). In our experiments, amounts of glycyrrhetinic acid in the preparations were less than the assay detection limit. However, we found considerable amounts of glycyrrhizin in the three preparations as shown in Table 2. Glycyrrhizin contained in the daily doses of the preparations varied from 60 to 66 mg, but there was not a considerable difference between the remedies.

Effects on prednisolone pharmacokinetics

Mean serum concentrations vs time profiles of prednisolone and prednisone following administration of prednisolone alone (control study) and in combination with the individual preparations (test study) are shown in Fig. 1. Prednisolone concentrations in the test study as compared with the control study decreased in the Sho-saiko-To group (P < 0.05), increased in the Saiboku-To group (P < 0.05), and remained unchanged in the Sairei-To group. Prednisone concentrations changed significantly only in the Sho-saiko-To group (P < 0.05), while they remained unchanged in the other groups.

Different effects of the three preparations on pharmacokinetic parameters of prednisolone are given in Table 3. The control parameters were comparable with those reported by Schrier & Gambertoglio (1991). Sho-saiko-To and Saiboku-To treatment affected the parameters inversely and significantly, whereas Sairei-To treatment showed no considerable changes.

In the Sho-saiko-To group, prednisolone AUC decreased by 16.6% (P < 0.05) and the prednisone AUC increased by

Table 3. Comparison o				

Group		$AUC_{0-10} (\mu g h m L^{-1})$		AUC ₀₋₁₀ ratio	CL	tį	Vd
		Prednisolone	Prednisone	Prednisone/ prednisolone	$(L h^{-1})$	(h)	(L)
Sho-saiko-	-To						
(n = 6)	Control Test	$\begin{array}{c} 0.94 \pm 0.13 \\ 0.78 \pm 0.10* \end{array}$	$\begin{array}{c} 0.14 \pm 0.03 \\ 0.19 \pm 0.01 \end{array}$	$0.15 \pm 0.03 \\ 0.25 \pm 0.03**$	10.9 ± 1.6 $13.0 \pm 1.6*$	$2.84 \pm 0.20 \\ 2.74 \pm 0.27$	43.4 ± 7.1 55.4 ± 6.4*
Saiboku-T	o						
(n = 9)	Control Test	$0.92 \pm 0.08 \\ 1.06 \pm 0.12$ **	$0.15 \pm 0.02 \\ 0.14 \pm 0.02$	$0.16 \pm 0.02 \\ 0.14 \pm 0.02^{**}$	10.9 ± 0.9 $9.6 \pm 1.1**$	2.69 ± 0.29 2.82 ± 0.23	$42.2 \pm 4.6 \\ 38.7 \pm 2.7$
Sairei-To							
(n = 7)	Control Test	$\begin{array}{c} 0.95 \pm 0.12 \\ 0.91 \pm 0.13 \end{array}$	$0.14 \pm 0.02 \\ 0.15 \pm 0.02$	$0.15 \pm 0.03 \\ 0.16 \pm 0.02$	10.7 ± 1.5 11.1 ± 1.5	$2.80 \pm 0.21 \\ 2.73 \pm 0.22$	$43.6 \pm 6.5 \\ 43.6 \pm 3.9$

*P < 0.05, **P < 0.01 compared with control.




FIG. 2. Plot of concentration ratios of prednisone/prednisolone after oral administration of 10 mg prednisolone alone (control ---) and with the test preparation (–). *P < 0.05 **P < 0.001 compared with control values.

19.4% (P < 0.05). The elimination half-life (t_2) of prednisolone in this group tended to shorten but the change was not statistically significant.

In the Saiboku-To group, parameters changed in the opposite direction. Prednisolone AUC increased significantly by 14% (P < 0.01), while prednisone AUC tended to decrease. Also, $t_{\frac{1}{2}}$ tended to lengthen, but not significantly.

Changes in ratio of prednisone/prednisolone

Time profiles of mean serum concentration ratios of prednisone to prednisolone with and without co-administration of the preparations were compared between the treatment groups (Fig. 2). Concentration ratios after the treatment increased in the Sho-saiko-To group, decreased in the Saiboku-To group, and remained unchanged in the Sairei-To group. This suggested that interconversion of prednisolone to prednisone is promoted by Sho-saiko-To and inhibited by Saiboku-To. The magnitude of these modifications was deduced from AUC ratios of prednisone/ prednisolone as described *in Table 3. Observed AUC ratios in the Sho-saiko-To group showed a 67% increase after the treatment (P < 0.01), whereas those in the Saiboku-To group showed a 13% decrease. These data strongly suggested that the converting enzyme activity was modified differently in the two groups.

Effects on endogenous cortisol and cortisone

Effects of the preparations on endogenous cortisol and cortisone concentrations, and their ratio (cortisone/cortisol) were compared (Table 4). Mean cortisol concentration in the Sho-saiko-To and Sairei-To groups decreased after the treatment (P < 0.05), but tended to increase in the Saiboku-To group. Although effects of the treatment on cortisone concentrations were not statistically significant, changes in the concentration ratios, cortisone/cortisol, were comparable with those of prednisone/prednisolone. The mean concentration ratios increased by 72% in the Sho-saiko-To group (P < 0.05), decreased by 15.4% in the Saiboku-To group (P < 0.05), and remained unchanged in the Sairei-To group (Table 4).

Discussion

G. glabra (liquorice) derivatives such as glycyrrhizin and glycyrrhetinic acid have been known to inhibit 11β -hydroxysteroid dehydrogenase (Monder et al 1989). Intravenous administration of glycyrrhizin at a dose of 40 mg

Group		Serum concentra	Concentration ratio		
		Cortisol	Cortisone	cortisone/cortisol	
Sho-saiko-	То				
(n = 6)	Control	101.1 ± 27.3	24.1 ± 6.7	0.25 ± 0.10	
. ,	Test	$75.3 \pm 30.0*$	27.1 ± 5.6	$0.43 \pm 0.21*$	
Saiboku-T	0				
(n = 9)	Control	119.1 ± 45.4	27.7 ± 7.1	0.26 ± 0.08	
· /	Test	131.9 ± 63.1	25.1 ± 4.6	$0.22 \pm 0.08*$	
Sairei-To					
(n = 7)	Control	97.9 ± 23.6	20.9 ± 3.2	0.23 ± 0.09	
()	Test	$88.2 \pm 26.6*$	18.5 ± 1.8	0.23 ± 0.06	

Table 4. Comparison of serum cortisol and cortisone concentrations in subjects receiving Sho-saiko-To, Saiboku-To and Sairei-To.

*P < 0.05 compared with control.

revealed no effect on the diurnal rhythm of endogenous cortisol, while it increased AUC and the half-life of prednisolone (Ojima et al 1990). Oral administration of glycyrrhetinic acid for one week at daily doses of 500 mg decreased the cortisone/cortisol ratio (Mackenzie et al 1990). These results suggest that oral administration of mixed herbal remedies containing liquorice might also alter prednisolone pharmacokinetics.

The three herbal remedies tested in this study contained considerable amounts of glycyrrhizin, 60–66 mg, in their daily doses. Reported bioavailability of glycyrrhizin when administered orally is very low (Groot et al 1988) unless the glycoside is converted to its aglycone, glycyrrhetinic acid. If this occurs in the intestinal tract, then glycyrrhetinic acid may contribute to steroid metabolism via its potent inhibition of 11β -hydroxysteroid dehydrogenase. We considered that this predictable effect of glycyrrhetinic acid may be equally displayed by the three preparations in this study because they contained similar amounts of the glycoside in their daily doses.

Our most important finding is that the effects of the three preparations on prednisolone pharmacokinetics were significantly different.

Our results support the idea that unknown modifiers of the hydrogenase including promoters and inhibitors will affect the pharmacokinetics of prednisolone. Sho-saiko-To is characterized by promotion of 11β -hydroxysteroid dehydrogenase, resulting in transformation of prednisolone into inactive prednisone whereas Saiboku-To is characterized by inhibition of the enzyme. A similar situation may occur for Sairei-To, even though this medicine had no effect on apparent prednisolone pharmacokinetics.

The lack of statistical differences observed for endogenous hormones cortisol and cortisone may depend on differences in major metabolic enzymes between cortisol and prednisolone; the former is subjected primarily to A-ring hydrogenase and the latter to 11β -hydroxysteroid dehydrogenase (Rodchenkov et al 1991). Another reason may be the negative feedback controls that hold cortisol concentrations at intrinsic physiological levels.

We ruled out the possibility of other pathways to regulate prednisolone pharmacokinetics as follows. Prednisolone pharmacokinetics are influenced by agents which modify microsomal liver enzymes such as 6β -hydroxylase, or protein binding (Frey & Frey 1990). Although ketoconazol and oral contraceptive steroids increase plasma prednisolone concentration by 6β -hydroxylase inhibition and plasma transcortin induction, respectively, these pharmacological changes do affect prednisolone interconversion as assessed by the prednisone/prednisolone ratio (Frey & Frey 1990). On the contrary, 6β -hydroxylase inducers such as phenytoin, barbiturates, carbamazepin, and rifampicin decrease the plasma prednisolone concentration and modify the interconversion. In this case, however, the concentration ratio prednisone/prednisolone decreased despite declining plasma prednisolone concentration (Frey & Frey 1990). Although the reason for this is still unclear, the contribution of 11β hydroxysteroid dehydrogenase is unlikely. Thus, the relationships between the plasma prednisolone concentration and prednisone/prednisolone ratio in these inducers could not explain the situation for the traditional Chinese medicine.

Multiple chemical components in addition to glycyrrhizin could play a role in the modifications. Saiboku-To contains at least three additional herbal extracts in addition to the seven constituents of Sho-saiko-To, and suggests the existence of additional inhibitory candidates in the form, such as magnolol. Magnolol has been detected in urine at considerable concentrations in subjects receiving Saiboku-To (Homma et al 1992). Higher urinary excretion of magnolol was characteristic of the responsive asthmatic patients rather than non-responsive ones in this treatment (Homma et al 1993a, b), and inhibition of 11β -hydroxysteroid dehydrogenase in-vitro has recently been demonstrated by us using rat liver homogenates (Homma et al 1994). We suggest that the clinical effect of this preparation on steroid dehydrogenase may also be attributable to magnolol.

The three preparations used in this study are recommended for use in steroid dose-sparing, and are thought to act by inhibition of glucocorticoid metabolism by liquorice triterpenoids such as glycyrrhizin and glycyrrhetinic acid (Monder et al 1989; Teelucksingh et al 1990), activation of ACTH secretion and thus elevation of endogenous serum cortisol (Hiai et al 1981; Yokoyama et al 1983), or by replacing endogenous steroids (Abe et al 1981; Nagano et al 1988). The first mechanism was partly confirmed in the case of Saiboku-To, with magnolol as the inhibitor, but this mechanism does not operate for Sho-saiko-To or Sairei-To. The second mechanism is unlikely as we could not detect any elevation of endogenous cortisol. The third mechanism may take place to a certain extent, because the remedies contain some anti-inflammatory (Toda et al 1988) or antiallergic (Koda et al 1982; Nishiyori et al 1983) components which we have shown to be absorbed into the body after administration of these preparations (Homma et al 1992, 1993a).

Acknowledgements

The authors which to thank Miss C. Taniguchi for her technical assistance. This work was supported in part by the Ministry of Education in Japan (Grant-in-Aid for Scientific Research No. 0385743).

References

- Abe, H., Konishi, Y., Arichi, S. (1981) Effect of Sairei-To on antiinflammatory action of glucocorticoid. Folia Pharmacol. Jpn. 78: 465–470 (in Japanese)
- Fauci, A. S., Dale, D. C., Balow, J. E. (1976) Glucocorticoid therapy: mechanisms of action and clinical considerations. Ann. Intern. Med. 54: 304–315
- Frey, B. M., Frey, F. J. (1990) Clinical pharmacokinetics of prednisone and prednisolone. Clin. Pharmacokinet. 19: 126–146
- Groot, G. D., Koops., R., Hogendoorn, E. A., Goewie, C. E., Savelkoul, T. J. F., Vioten, P. V. (1988) Improvement of selectivity and sensitivity by column switching in the determination of glycyrrhizin and glycyrrhetinic acid in human plasma by high-performance liquid chromatography. J. Chromatogr. 456: 71-81
- Hiai, S., Yokoyama, H., Nagasawa, T., Oura, H. (1981) Stimulation of the pituitary-adrenocortical axis by saikosaponin of *Bupleuri radix*. Chem. Pharm. Bull. 29: 495–499
- Homma, M., Oka, K., Yamada, T., Niitsuma, T., Itoh, H., Takahashi, N. (1992) A strategy for discovering biologically active compounds with high probability in traditional Chinese herb remedies: an application of Saiboku-To in bronchial asthma. Anal. Biochem. 202: 179–187

- Homma, M., Oka, K., Niitsuma, T., Itoh, H. (1993a) Pharmacokinetic evaluation of traditional Chinese herbal remedies. Lancet 19: 1595
- Homma, M., Oka, K., Kobayashi, H., Niitsuma, T., Yamamoto, S., Itoh, H., Takahashi, N. (1993b) Impact of free magnolol excretions in asthmatic patients who responded well to Saiboku-To, a Chinese herbal medicine. J. Pharm. Pharmacol. 45: 844–846
- Homma, M., Oka, K., Niitsuma, T., Itoh, H. (1994) A novel 11β hydroxysteroid dehydrogenase inhibitor contained in Saiboku-To, a herbal remedy for steroid-dependent bronchial asthma. J. Pharm. Pharmacol. 46: 305–309
- Koda, A., Nishiyori, T., Nagai, H., Matsuura, N., Tsuchiya, H. (1982) Anti-allergic action of crude drugs and blended Chinese traditional medicines. Folia Pharmacol. Jpn. 80: 31-41 (in Japanese)
- Mackenzie, M. A., Hoefnagels, W. L. H., Jansen, R. W. M. M., Benraad, T. J., Kloppenborg, P. W. C. (1990) The influence of glycyrrhetinic acid on plasma cortisol and cortisone in healthy young volunteers. J. Clin. Endocrinol. Metab. 70: 1637–1643
- Monder, C., Stewart, P. M., Lakshmi, V., Valentino, R., Burt, D., Edwards, C. R. W. (1989) Licorice inhibits corticosteroid 11βdehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 125: 1046–1053
- Nagano, H., Kobayashi, S., Nakajima, S., Egashira, T. (1988) Long-term clinical evaluation of Saiboku-To, an anti-asthmatic agent, in treatment of bronchial asthma (multicenter open trial). Respiration 7: 76–87 (in Japanese)
- Nishiyori, T., Nakatomi, I., Matsuura, N., Nagai, H., Koda, A. (1983) Effect of Chinese blended medicine, Saiboku-To, on type IV allergic reaction. Jpn. J. Allergol. 32: 317–323
- Ogawa, S., Yoshida, A., Mitani, Y. (1976) Analytical studies on the active constituents in crude drugs II. Determination of glycyrrhizin in pharmaceutical preparations including Glycyrrrhizae Radix by high-speed liquid chromatography. Yakugaku Zasshi 96: 1488-1491 (in Japanese)

Ojima, M., Satoh, K., Gomibuchi, T. (1990) The inhibition effects

of glycyrrhizin and glycyrrhetinic acid on metabolism of cortisol and prednisolone. Folia Endocrinol. 66: 584-596 (in Japanese)

- Oka, K., Ohki, N., Noguchi, M. (1984) Extraction-monitoring and rapid flow fractionation for determination of serum corticosteroids. Anal. Chem. 56: 2614–2617
- Oka, K., Noguchi, M., Kitamura, T., Shima, S. (1987) Liquid chromatography and radio-immunoassay compared for determination of cortisol and corticosterone in plasma after a dexamethasone suppression test. Clin. Chem. 33: 1639–1642
- Rodchenkov, G. M., Vedenin, A. N., Uralets, V. P., Semenov, V. A. (1991) Characterization of prednisone, prednisolone and their metabolites by gas chromatography-mass spectrometry. J. Chromatogr. Biomed. Appl. 565: 45-51
- Schrier, R. W., Gambertoglio, J. G. (1991) Handbook of Drug Therapy in Liver and Kidney Disease. Little Brown, Boston, pp 194–198
- Senaga, R., Kawashima, S. (1986) Clinical influences of Sairei-To on renal diseases in children. J. Med. Pharm. Soc. Wakanyaku 3: 45-50 (in Japanese)
- Tani, T., Ohno, T., Inoue, K., Katsuki, T., Arichi, S. (1986) Effect of crude drugs and their prescription on the blood rheology affected by glucocorticoid treatment IV. Effect of Sho-saiko-To, Dai-saiko-To and their constituent crude drugs on adverse reactions in betamethasone treated rat. Yakugaku Zasshi 106: 808-817 (in Japanese)
- Teelucksingh, S., Mackie, A. D. R., Burt, D., Macintyre, M. A., Brett, L., Edwards, C. R. W. (1990) Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet 335: 1060-1063
- Toda, S., Kimura, M., Ohnishi, M., Nakanishi, K. (1988) Effect of the Chinese herbal medicine "Saiboku-To" on histamine release and the degranulation from mouse peritoneal mast cell induced by compound 48/80. J. Ethnopharmacol. 24: 303-309
- Yokoyama, H., Hiai, S., Oura, H. (1983) Effect of saikosaponins on dexamethasone suppression of the pituitary-adrenocortical system. Chem. Pharm. Bull. 32: 1224–1227